Our People

 

We have deep expertise in the study of tendon diseases and a track record of success in drug development and commercialization.

two-people-standing-on-giant-peaks.jpg
bg-gradient-top-SHORT.jpg

Our team has discovered that miR-29a acts through multiple pathways to treat chronic tendon disease

 
dark-blue-background-color.jpg